Combined cellular and biochemical profiling of Bruton’s tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers

20250 citationsJournal Articlegold Open Access

Authors

Daphne J. F. Kluitmans · Oncolie

Janneke J. T. M. Melis · Oncolie

Esmee van den Bossche · Oncolie

Jacob Ytsma · Oncolie

Jeroen A.D.M. de Roos · Oncolie

Oscar P. J. van Linden · Vrije Universiteit Amsterdam

Yvonne Grobben · Oncolie

Abstract

Combined cancer cell panel and biochemical profiling reveals previously underappreciated cross-reactivities of nemtabrutinib indicating a potential application in MAPK-driven cancers.

Topics & Keywords

Chronic Lymphocytic Leukemia Research PI3K/AKT/mTOR signaling in cancer Lymphoma Diagnosis and Treatment

Publication Details

Published in: Frontiers in Oncology

Volume 15, pp. 1667291-1667291

DOI: 10.3389/fonc.2025.1667291

Field-Weighted Citation Impact: 0.00

Command Palette

Combined cellular and biochemical profiling of Bruton’s tyrosine kinase inhibitor nemtabrutinib reveals potential application in MAPK-driven cancers

Authors

Abstract

Topics & Keywords

Publication Details